

Yiyi Yan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1907596/publications.pdf>

Version: 2024-02-01

19
papers

508
citations

1163117

8
h-index

940533

16
g-index

19
all docs

19
docs citations

19
times ranked

1228
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding Suboptimal Response to Immune Checkpoint Inhibitors. <i>Advanced Biology</i> , 2023, 7, e2101319.	2.5	5
2	Resolving the Heterogeneous Tumor-Centric Cellular Neighborhood through Multiplexed, Spatial Paracrine Interactions in the Setting of Immune Checkpoint Blockade. <i>Cancer Research Communications</i> , 2022, 2, 78-89.	1.7	2
3	Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade. <i>Advances in Radiation Oncology</i> , 2022, 7, 100931.	1.2	4
4	NKG7 Is a T-cellâ€™Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 162-181.	3.4	26
5	Immuneâ€™related hematologic adverse events in the context of immune checkpoint inhibitor therapy. <i>American Journal of Hematology</i> , 2021, 96, E362-E367.	4.1	4
6	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 364-375.	1.2	42
7	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. <i>Journal of Immunotherapy</i> , 2020, 8, e001113.		32
8	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 561083.	4.8	12
9	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
10	Paradox-driven adventures in the development of cancer immunology and immunotherapy. <i>Genes and Diseases</i> , 2019, 6, 224-231.	3.4	3
11	Understanding heterogeneous tumor microenvironment in metastatic melanoma. <i>PLoS ONE</i> , 2019, 14, e0216485.	2.5	36
12	Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. <i>Supportive Care in Cancer</i> , 2019, 27, 3869-3875.	2.2	9
13	The role of serum lactate dehydrogenase level as a prognostic indicator in resected, high risk melanoma. <i>Dermatologic Therapy</i> , 2019, 32, e12813.	1.7	0
14	Neoadjuvant systemic therapy for regionally advanced melanoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 1164-1169.	1.7	12
15	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 1739.	4.8	174
16	CX3CR1 identifies PD-1 therapyâ€™responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. <i>JCI Insight</i> , 2018, 3, .	5.0	106
17	A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. <i>SOJ Immunology</i> , 2017, 5, 1-5.	0.2	0
18	CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. <i>Oncotarget</i> , 2016, 7, 70223-70231.	1.8	33

#	ARTICLE	IF	CITATIONS
19	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. <i>OncoTargets and Therapy</i> , 2015, 8, 2949.	2.0	7